13vPnC

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Vaccines

Conditions

Vaccines

Trial Timeline

May 31, 2018 → Dec 20, 2019

About 13vPnC

13vPnC is a approved stage product being developed by Pfizer for Vaccines. The current trial status is completed. This product is registered under clinical trial identifier NCT03548337. Target conditions include Vaccines.

What happened to similar drugs?

9 of 20 similar drugs in Vaccines were approved

Approved (9) Terminated (0) Active (11)

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT03777865ApprovedCompleted
NCT03548337ApprovedCompleted
NCT00562354Phase 3Completed
NCT00574795Phase 3Completed

Competing Products

20 competing products in Vaccines

See all competitors
ProductCompanyStageHype Score
Vaxelis™MerckApproved
43
21-valent pneumococcal conjugate vaccineMerckApproved
50
Gardasil-9MerckApproved
39
Human papillomavirus 9-valent vaccine, recombinant + human papillomavirus vaccine, recombinantMerckApproved
50
13-valent pneumococcal conjugate vaccine + 7-valent pneumococcal conjugate vaccinePfizerPhase 3
40
13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccinePfizerPhase 3
40
13vPnC + 23vPSPfizerPhase 3
40
13-valent Pneumococcal Conjugate VaccinePfizerPhase 3
40
pneumococcus conjugate vaccine 7 valent to reduce carriagePfizerApproved
43
13-valent Pneumococcal Conjugate Vaccine + 7vPnCPfizerPhase 3
40
13-valent Pneumococcal Conjugate Vaccine + 7vPnC + Pediacel + NeisVac-C + MenitorixPfizerPhase 3
40
rLP2086 + MCV4 + Tdap + MCV4 + Tdap + saline + rLP2086 + salinePfizerPhase 2
35
13 valent pneumococcal conjugate vaccine + 7vPnc pneumococcal conjugate vaccinePfizerPhase 3
40
13-valent pneumococcal conjugate vaccine + 7-valent pneumococcal conjugate vaccine + PentavacPfizerPhase 3
40
pneumococcus conjugate vaccinePfizerApproved
43
13 valent Pneumococcal Conjugate Vaccine + 13 valent Pneumococcal Conjugate Vaccine + 13 valent Pneumococcal Conjugate Vaccine + 23-valent Pneumococcal Polysaccharide Vaccine + 23-valent Pneumococcal Polysaccharide VaccinePfizerPhase 3
40
Prevenar + Infanrix hexaPfizerApproved
43
13-valent Pneumococcal Conjugate VaccinePfizerPhase 2
35
13vPnCPfizerApproved
43
13 valent pneumococcal conjugate vaccine with Polysorbate 80 + 13 valent pneumococcal conjugate vaccine without Polysorbate 80PfizerPhase 3
40